Literature DB >> 16797935

Antibiotic cements in articular prostheses: current orthopaedic concepts.

F Langlais1, N Belot, M Ropars, H Thomazeau, J C Lambotte, G Cathelineau.   

Abstract

The possibilities and limits of antibiotic cements (ACs) have been assessed by many researchers. ACs are now approved by many drug agencies, including the US Food and Drug Administration (approval in 2003), with widespread use in prophylaxis and curative treatments. Laboratory experiments have achieved satisfactory antibiotic delivery without impairing the mechanical properties of ACs. Implantation in large animals (e.g. sheep) showed an antibiotic concentration in the bone cortex four times the minimal inhibitory concentration (MIC) 6 months after implantation. Human pharmacokinetics during total hip replacement (THR) show antibiotic concentrations 20 times the MIC in drainage fluids. No toxic concentrations have been detected in blood or urine, and no allergies, toxic effects, mechanical failures or selection of resistant microorganisms have been observed. Antibioprophylaxis has been assessed in prospective studies in over 1600 cases. In data from the Scandinavian arthroplasty registers, with an exhaustive follow-up of more than 240000 THRs, infection rate was reduced by ca. 50% (0.9% compared with 1.9%). In prostheses with severe infection, use of AC increases the infection control rate from 86% to 93% when using two-stage prosthetic exchanges. In moderate infection, a similar infection control rate (86%) was achieved either by two-stage exchange without local antibiotic or by one-stage exchange with AC; however, one-stage exchange achieved better functional results at lower cost and with reduced pain and hospital stay. Therefore, AC prophylaxis is widely used in countries with prostheses registers (Northern Europe), and use of ACs as treatment for infected prostheses is often considered as the gold standard in the EU and North America. However, AC is only an adjuvant treatment, and excision of infected and devascularized tissues as well as systemic antibiotic treatment managed by a multidisciplinary team remain the main factors of infection control.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16797935     DOI: 10.1016/j.ijantimicag.2006.05.020

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  5 in total

1.  Antibiotic-associated complications following lower limb arthroplasty: a comparison of two prophylactic regimes.

Authors:  S Craxford; E Bayley; M Needoff
Journal:  Eur J Orthop Surg Traumatol       Date:  2013-11-01

2.  Infection in fracture fixation: can we influence infection rates through implant design?

Authors:  T Fintan Moriarty; U Schlegel; S Perren; R Geoff Richards
Journal:  J Mater Sci Mater Med       Date:  2009-10-20       Impact factor: 3.896

3.  Dual mobility cemented cups have low dislocation rates in THA revisions.

Authors:  Frantz L Langlais; Mickaël Ropars; François Gaucher; Thierry Musset; Olivier Chaix
Journal:  Clin Orthop Relat Res       Date:  2008-01-10       Impact factor: 4.176

4.  Prosthesis infections after orthopedic joint replacement: the possible role of bacterial biofilms.

Authors:  Zhijun Song; Lotte Borgwardt; Niels Høiby; Hong Wu; Torben Sandberg Sørensen; Arne Borgwardt
Journal:  Orthop Rev (Pavia)       Date:  2013-06-14

5.  Evaluation of the Effect of Ciprofloxacin and Vancomycin on Mechanical Properties of PMMA Cement; a Preliminary Study on Molecular Weight.

Authors:  Marzieh Gandomkarzadeh; Hamid Reza Moghimi; Arash Mahboubi
Journal:  Sci Rep       Date:  2020-03-04       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.